Accelerate Growth The Xentria Meitheal Advantage

Immunology. Study Phase : Phase I/ Phase II. Recipient : Xentria. Deal Size : $680.0 million. Deal Type : Licensing Agreement. DEALS_DEV arrow-down · Xentria ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... 01. Xentria · U.S.A arrow. Post Enquiry. Pharma, Lab & Chemical Expo. Not Confirmed. Xentria ... Xentria · U.S.A ... Meitheal Pharmaceuticals. Deal Size : $680.0 ... Xentria's Multi-Year Licensing Agreement with Meitheal. By Martina Bellini. Perkins Coie advised Xentria Inc. on the deal. Xentria Inc., a clinical-stage ... Meitheal Pharmaceuticals, Chicago, IL, Generics. Novian Health, Chicago, IL ... Xentria, Chicago, IL, Biologics & Biosimilars, Monoclonal Antibody. Xeris ... Xentria, Meitheal, Kinevant. Introduction. Current Endpoints. 17:00 - 17:05. 17:05 17:45. 17:05 17:15. ➤ Pulmonary Function Testing & Imaging. Meitheal Pharmaceuticals to commercialize novel biologic XTMAB-16 for pulmonary sarcoidosis in North America. Proposed Mechansim Of Action. CHO cell line Xentria Inc./Meitheal. Pharmaceuticals Inc. In clinical trials. Molecule. Innovator product (company) Biosimilars. Company. Status. Omalizumab. Xolair® ( ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... Xentria entered into an exclusive multi-year licensing agreement with Meitheal Pharmaceuticals to commercialize its lead candidate and novel ...